Sushil Jain
Medical Oncology · Fort Wayne, INNPI 1497749238
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 83 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 21 manufacturers reported payments, led by Takeda Pharmaceuticals U.S.A., Inc. at 33.3% of the total. Reporting peaked in 2019 at $698 and has fallen 57.1% since, to $299 in 2025. That places this record below the midpoint for medical oncology clinicians in IN, where the typical reported total is $2,472.
Across 83 payments — averaging $20.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Takeda Pharmaceuticals U.S.A., Inc.$580
- Merck$201
- Lilly USA, LLC$179
- Eisai Inc.$156
- Genentech USA, Inc.$150
- Bayer$96
- plus $378 from 15 others
Across 58 payments — averaging $6275.06 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Merck$335K
- Incyte Corporation$29K
What the payments were for
- Food & beverage$1,741100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc. | 26 | $580 |
| Merck | 19 | $201 |
| Lilly USA, LLC | 9 | $179 |
| Eisai Inc. | 4 | $156 |
| Genentech USA, Inc. | 3 | $150 |
| Bayer | 1 | $96 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 5 | $86 |
| AbbVie | 3 | $68 |
| Otsuka America Pharmaceutical, Inc. | 1 | $27 |
| Daiichi Sankyo Inc. | 1 | $24 |
| AstraZeneca | 1 | $21 |
| Intercept Pharmaceuticals, Inc. | 1 | $21 |
| Exact Sciences | 1 | $17 |
| Ironwood Pharmaceuticals, Inc | 1 | $17 |
| Exelixis Inc. | 1 | $16 |
| Sandoz | 1 | $16 |
| Nestle Healthcare Nutrition Inc. | 1 | $14 |
| Kyowa Kirin, Inc. | 1 | $14 |
| Shire North American Group Inc | 1 | $12 |
| E.r. Squibb & Sons, L.L.C. | 1 | $12 |
| Novartis | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,741 in reported general payments places this provider in the 40th percentile of 67 medical oncology providers in Indiana.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 11 | $6,783 |
| XareltoRivaroxaban | 15 | $4,447 |
| Sucralfate | 17 | $1,796 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 15 | $1,030 |
| Omeprazole | 36 | $513 |
| Aripiprazole | 15 | $429 |
| Gabapentin | 12 | $362 |
| Amlodipine Besylate | 35 | $353 |
| Mirtazapine | 22 | $213 |
| Ondansetron Hcl | 15 | $206 |
| Metoprolol Tartrate | 21 | $190 |
| Atorvastatin Calcium | 19 | $169 |
| Pantoprazole Sodium | 12 | $96 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga | $21 | $6,78311 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 67 medical oncology providers in Indiana.
Other medical oncology in Fort Wayne
- Sunil BabuFort Wayne$166K
- Farrukh AdhamiFort Wayne$35K
- Takefumi KomiyaFort Wayne$11K
- Costantine AlbanyLafayette$212K
- Natraj AmmakkanavarIndianapolis$129K
- Rafat AnsariMishawaka$90K
- Bert OneilIndianapolis$89K
- Pablo BedanoIndianapolis$52K
- Gregory SmithIndianapolis$46K
- Ashwin VasudevamurthyIndianapolis$44K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.